Am J Transplant, Volume 18, Suppl 3 Archives - Page 94 of 211 - ATC Abstracts

2018 American Transplant Congress
CMV-Specific Cell-Mediated Immunity after Valgancyclovir Prophylaxis Predicts Late Onset CMV Infection in Kidney Transplant Patients
M. Jarque,¹ E. Crespo,¹ E. Melilli,² A. Manonelles,² N. Montero,² S. Luque,¹ J. Cruzado,^1,2 J. Grinyo,^1,2 O. Bestard.^1,2
¹Experimental Nephrology Laboratory, IDIBELL, Barcelona, Spain; ²Nephrology Department, Bellvitge University Hospital, Barcelona, Spain.
Background: There is currently no means to predict late-onset CMV infection after a long course of post-transplant Valgancyclovir prophylaxis therapy and its development still negatively…
2018 American Transplant Congress
Pharmacological Defatting of Steatotic Human Livers Using a Novel Perfusion Solution during Normothermic Machine Perfusion
Y. Boteon,^1,2 J. Attard,^1,2 R. Laing,^1,2 A. Boteon,¹ R. Bhogal,¹ G. Reynold,² D. Neil,¹ H. Mergental,¹ D. Mirza,¹ S. Afford.²
¹National Institute for Health Research, Birmingham Liver Biomedical Research Centre, University of Birmingham, Institute of Immunology and Immunotherapy, Birmingham, United Kingdom; ²Liver Unit, Queen Elizabeth Hospital, University Hospitals Birmingham, Birmingham, United Kingdom.
Introduction: Steatosis is the leading reason for donor livers discarding and contributes significantly to the worsening shortage of organs for transplantation. Steatotic livers commonly fail…
2018 American Transplant Congress
Clinical and Pathological Findings in Hepatitis C Positive Renal Transplant Recipients Following Alemtuzumab Induction
S. Jonchhe, J. Husson, A. Haririan, B. Ravichandran.
University of Maryland Medical Center, Baltimore.
BackgroundHistorically, renal transplant recipients (RTRs) with chronic hepatitis C (HCV) have worse long-term outcomes. Induction with alemtuzumab (ALM) in HCV positive RTRs has been postulated…
2018 American Transplant Congress
Assessment and Outcomes of Medication Nonadherence in Pediatric Kidney Transplant Recipients: Results from the IMPACT Study
A. Dokras,¹ M. Pearl,¹ J. Peipert,¹ P. Grimm,⁴ B. Warshaw,² E. Chambers,³ A. Kirk,³ R. Ettenger.¹
¹University of California, Los Angeles, Los Angeles, CA; ²Children's Healthcare of Atlanta and Emory University, Atlanta, GA; ³Duke University, Durham, NC; ⁴Stanford University, Palo Alto, CA.
OBJECTIVE: Medication nonadherence (MNA) plays a key role in transplant (Tx) survival in pediatric kidney patients (pts). However, identification of MNA is challenging and tools…
2018 American Transplant Congress
Impact of Direct Acting Antivirals of Hepatitis C Virus Therapy on Tacrolimus Dosing Post-Liver Transplant
A. Bixby, L. Fitzgerald, R. Leek, J. Mellinger, S. Tischer.
Michigan Medicine, Ann Arbor, MI.
Background: Direct acting antivirals (DAA) have transformed hepatitis C virus (HCV) management post-liver transplant (LT). As HCV clears, hepatic metabolism improves, resulting in decreased tacrolimus…
2018 American Transplant Congress
Inflammation in Fibrotic Areas (i-IF/TA) Identifies a T Cell-Mediated Rejection Component of IF/TA with Poor Kidney Allograft Outcome
D. Viglietti, O. Aubert, J-.P. Duong Van Huyen, A. Loupy, C. Lefaucheur.
Paris Translational Research Center for Organ Transplantation, Paris, France.
Addressing the etiological heterogeneity of interstitial fibrosis in kidney allografts represents an important challenge to improve long-term transplant outcomes. We investigated the determinants, clinical and…
2018 American Transplant Congress
Genomic Modifications Associated with Epstein Barr Virus+ Post-Transplant Lymphoproliferative Disorder
M. McPherson,¹ Y. Balachandran,¹ S. Boyd,² H. Zimmermann,³ R. Trappe,³ C. Esquivel,¹ S. Krams,¹ O. Martinez.¹
¹Department of Surgery, Stanford University School of Medicine, Stanford, CA; ²Department of Pathology, Stanford University School of Medicine, Stanford, CA; ³Department of Haematology and Oncology, DIAKO Ev. Diakonie-Krankenhaus Bremen, Bremen, Germany.
Epstein Barr Virus (EBV) is nearly ubiquitous in the human population, yet EBV infection is typically asymptomatic. Nevertheless, immunosuppressed transplant recipients are susceptible to EBV+…
2018 American Transplant Congress
T-bet and STAT6 Double Deficiency Favors IL-17 Immunity after Lung Transplantation
F. Liang,¹ R. Chen,¹ Q. Chen,² J. Ochando,³ Y. Ding,¹ J. Xu.¹
¹Department of Immunology, Capital Medical University, Beijing, China; ²Department of Thoracic Surgery, Chaoyang Hospital, Beijing, China; ³Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.
Background: The long-term success of lung transplantation is mainly limited by the development of obliterative bronchiolitis (OB) in which IL-17 plays a critical role. Direct…
2018 American Transplant Congress
Outcomes of Organ Transplantation from Donors with Cancer History
Z. Guo,¹ X. He,¹ S. Huang.¹
¹Organ Transplant Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; ²Guangdong Provincial Key Laboratory of Organ Donation and Transplant Immunology, Sun Yat-sen University, Guangzhou, China; ³Guangdong Provincial International Cooperation Base of Science and Technology, Sun Yat-sen University, Guangzhou, China.
Purpose: The inherent challenges of selecting an acceptable donor for each of the increasing numbers and acuity of recipients has led programs to take increased…
2018 American Transplant Congress
First Birth after Uterus Transplant in the US
L. Johannesson, R. Gunby, Jr., T. Anthony, G. McKenna, E. Koon, A. Warren, G. dePrisco, J. Mitchell, J. Putman, K. Wallis, G. Klintmalm, G. Testa.
Baylor University Medical Center, Dallas, TX.
Introduction - Uterus Transplantation (UTx) is the first available treatment for women with Absolute Uterine Infertility (AUI). It allows the affected female to carry her…